ADENOVIRUS DIAGNOSTIC TESTING MARKET ANALYSIS

Market Challenges And Opportunities

Adenovirus Diagnostic Testing Market – Driver

Adenoviruses are associated with a variety of nonspecific manifestations and clinical syndromes, thus diagnosis based upon clinical criteria alone is challenging. Diagnosis is most accurate when the infection shows outbreak symptoms or individuals show serious disease manifestations. Validation of adenovirus infection is essential for identifying the most appropriate treatment to establish a prognosis and initiate infection control measures by using correct antiviral agents, thus making diagnosis of these viruses a vital procedure. This in turn, is expected to augment growth of the adenovirus diagnostic testing market. Generally, there are two types of adenoviruses namely, Type 4 and Type 7 that caused severe outbreaks of respiratory illness, especially among military recruits. Thus, adenovirus vaccine, containing Type 4 and Type 7, is thus approved for military personnel aged 17 to 50 years from 1971, to protect them against the illness caused by these two viruses. In the recent past, adenovirus infections were diagnose by cell culture, as the virus replicates efficiently in cell cultures. Monoclonal antibodies are also used to detect infected cells using direct fluorescence antibody assays. Amplification and detection of adenovirus DNA by polymerase chain reaction methods are also gaining popularity as laboratory methods to determine adenovirus infection. The rapid detection and quantitation of adenovirus DNA, especially by a sensitive PCR technique is expected to aid in the diagnosis and treatment monitoring of adenovirus infections, particularly in immunocompromised patients. This in turn, is expected to boost growth of the adenovirus diagnostic testing market during the forecast period.

Moreover, growing research and development of technologies for use in the diagnosis of acute respiratory infections of viral etiology is expected to fuel market growth. For instance, in 2014, DiaSorin launched its sixth LIAISON test for the qualitative detection of adenovirus in stool samples in markets outside the U.S. and the U.K., the test is an addition to the 5 most important tests of the stool testing panel, already available in the market (C. Difficile toxin A&B, C. Difficile GDH, Helicobacter Pylori, EHEC, and Rotavirus).